Missouri Courts Emphasize Finality as FDA Scrutinizes Clinical Trial Data

A recent slate of rulings from Missouri's appellate courts delivers a stark reminder on the fundamentals of appellate jurisdiction, with multiple appeals dismissed for lacking a "final judgment." Meanwhile, in the regulatory sphere, the U.S. Food and Drug Administration (FDA) has highlighted its rigorous standards for new drug applications, issuing a rejection letter to one company over data integrity concerns while providing a clear path forward for another. These developments, though in different legal arenas, underscore a shared theme: the critical importance of procedural precision and robust evidence, whether in a courtroom or a clinical trial.

The Unyielding Requirement of Finality in Missouri Appeals

For attorneys practicing in Missouri, a series of recent decisions serves as a masterclass on the jurisdictional prerequisite of finality. The Missouri Court of Appeals repeatedly drove home the principle that an appeal can only proceed from a judgment that "disposed of all matters as to all parties." A judgment that leaves issues unresolved, even if labeled "final" by a lower court, is insufficient to invoke appellate jurisdiction.

In Savannah Radmer vs. Missouri Department of Corrections , the Western District dismissed an appeal because the circuit court's judgment was silent on the plaintiff's prayers for prejudgment interest and attorney fees. Similarly, in Anita M. Beckmann, Appellant, v. Mary K. Wilson, et al. , the Eastern District found a judgment non-final because it failed to resolve pending counterclaims for slander of title and malicious prosecution. The court noted that resolution of the primary claim—a trust's no-contest clause—did not necessarily resolve the distinct issues raised in the counterclaims, which were slated for a future jury trial. These cases stand as a critical caution for litigators to ensure every claim, counterclaim, and request for relief is explicitly resolved before filing a notice of appeal.

Beyond finality, the courts also clarified other key procedural rules. In Phillip Weeks, Appellant, vs. City of St. Louis , the Supreme Court of Missouri articulated the high bar for challenging a judgment as against the weight of the evidence. The court stated that such a challenge requires a comprehensive analysis that presents all evidence supporting the judgment and demonstrates a complete lack of probative force for a necessary finding. The appellant's failure to adhere to this rigorous analytical framework rendered their arguments valueless.

Another crucial procedural takeaway came in State of Missouri, Appellant, vs. Amanda M. Mire , where the Supreme Court dismissed an interlocutory appeal as untimely. The court clarified that the clock for filing starts with the definitive ruling, which in this case was a docket entry "unequivocally" suppressing evidence, not a later formal order.

Regulatory Hurdles: FDA Demands Rigor in Drug Applications

In parallel, developments in the highly regulated pharmaceutical sector illustrate the FDA's exacting standards for data submitted in New Drug Applications (NDAs). Biohaven Pharmaceuticals received a Complete Response Letter (CRL) for its application for troriluzole, an investigational treatment for spinocerebellar ataxia (SCA), a rare neuromuscular disorder with no approved therapies.

According to Biohaven, the FDA’s rejection was not based on the drug's safety or efficacy profile but on the data supporting the application. The agency cited issues with the company's use of "real-world data and external controls," which it felt introduced "potential bias, design flaws, and lack of pre-specification and unmeasured confounding factors." This decision sends a clear signal to the pharmaceutical industry about the potential pitfalls of relying on non-traditional data sources to supplement or replace randomized controlled trial data, especially for a first-in-class approval. Biohaven is now expected to work with the agency to determine the next steps for the promising treatment.

In contrast, CervoMed received positive written feedback from the FDA regarding its proposed phase 3 trial for neflamapimod, a potential treatment for dementia with Lewy bodies (DLB). The agency aligned on key aspects of the trial design, giving the company a clear pathway to potentially support an NDA submission. CervoMed plans to initiate a single, global, randomized, double-blind, placebo-controlled trial in the second half of 2026. This juxtaposition of FDA actions demonstrates that while the regulatory path is narrow and demanding, clear and early communication with the agency can pave the way for a well-designed trial capable of producing the robust data required for approval.

Substantive Rulings Impacting Business and Employment Law

Beyond procedural matters, Missouri courts issued several substantive rulings with significant implications for legal practice.

Partnership and Arbitration: In Diana Maune vs. Marcus Raichle, Jr. , the Supreme Court of Missouri reaffirmed the state's adherence to the "aggregate theory" of partnerships. It held that a partnership has no legal existence separate from its partners. Consequently, when partners sign an agreement containing an arbitration clause—and a delegation clause giving the arbitrator power to decide arbitrability—the partnership and the partners' successors (including estates) are bound by it. The court vacated a lower court ruling and remanded the case with instructions to compel arbitration, reinforcing the power of delegation clauses.

Extraterritorial Limits of State Law: The Western District’s decision in Carrie Sciortino vs. Ozark National Life Insurance Company sets a clear geographic boundary for the Missouri Human Rights Act (MHRA). The court affirmed the dismissal of a discrimination claim brought by an employee who worked remotely from her home in Louisiana for a Missouri-based company. The court reasoned that Missouri statutes, absent express contrary text, "apply only within the boundaries of this state." Since the alleged harm occurred where the employee worked—Louisiana—the MHRA offered no remedy. This ruling is increasingly relevant in an era of remote work, providing clarity for employers on the reach of state-specific employment statutes.

Insurance and the Duty to Defend: In a major insurance coverage dispute, Certain Underwriters at Lloyd's London vs. Northrop Grumman Corporation , the Western District ruled that there is no duty to defend or indemnify for events that occur decades after insurance policies have expired. The court held that the "mere potential for liability" that triggers a duty to defend must arise from events within the policy period. The conduct of the insured's predecessor did not alter this fundamental principle, providing insurers with a strong defense against claims related to long-expired policies. This de novo review of contract interpretation reinforces that the policy's text is paramount.

Collectively, these legal and regulatory updates paint a picture of a system that demands precision. Whether drafting a final judgment, designing a clinical trial, or defining the scope of a contract, the message is clear: the details matter, procedure is paramount, and the evidence must be unassailable. For legal professionals, these cases offer not just updates on the law, but crucial lessons in the meticulous practice of it.